How Effective Is Stelara for Ulcerative Colitis?
Stelara (ustekinumab) treats moderate to severe ulcerative colitis in adults who haven't responded well to other therapies like TNF blockers. It targets IL-12 and IL-23 cytokines to reduce gut inflammation. In clinical trials, about 16% of patients achieved clinical remission at week 8 after IV induction, rising to 44% at week 44 with subcutaneous maintenance.[1] These rates beat placebo (5% at week 8, 24% at week 44).[1]
Clinical Remission and Response Rates from Key Trials
The UNIFI trial, a phase 3 study with 961 patients, showed:
- Induction phase (single IV dose): 15.6% remission vs. 5.3% placebo at week 8; 51% clinical response vs. 32% placebo.[1][2]
- Maintenance phase (every 8 or 12 weeks SC): 44% and 34% remission vs. 24% placebo at week 44.[1]
Endoscopic improvement occurred in 40% at week 44 (maintenance) vs. 13% placebo.[1] Real-world data from cohort studies report 30-50% remission rates after 1 year, varying by prior treatment exposure.[3]
How Stelara Compares to Other UC Drugs
| Drug | Class | Week 8 Remission (Induction) | Week 52/44 Remission (Maintenance) |
|------|-------|------------------------------|------------------------------------|
| Stelara | IL-12/23 inhibitor | 16%[1] | 44% (q8w)[1] |
| Entyvio (vedolizumab) | Gut integrin inhibitor | 17%[4] | 42%[4] |
| Humira (adalimumab) | TNF inhibitor | 13%[5] | 17%[5] |
| Xeljanz (tofacitinib) | JAK inhibitor | 19%[6] | 34%[6] |
Stelara matches or exceeds TNF inhibitors but trails some JAKs in speed; it's often used after TNF failure.[2]
When Do Patients See Results and How Long Do They Last?
Symptom relief (stool frequency, rectal bleeding) starts by week 2-6 in responders. Full remission builds over 8-44 weeks. Long-term data (up to 3 years) show sustained remission in 70-80% of week-8 responders on maintenance.[7] Durability drops if prior biologics failed.
Who Responds Best and What Limits Effectiveness?
Best outcomes in bio-naive patients (no prior biologics): 51% response at week 8 vs. 39% in bio-exposed.[1] Factors like high baseline CRP or deep ulcers predict poorer response. About 40-50% don't achieve remission; switching to another class (e.g., JAK) succeeds in half.[3]
Common Side Effects and Safety Concerns
Infections (7%), upper respiratory issues (5%), and headache (5%) top the list; serious infections in 3-5%.[1] No increased malignancy or mortality vs. placebo in trials up to 3 years.[7] Patients with active infections or TB risk should avoid it.
[1]: UNIFI Trial (NEJM, 2019)
[2]: FDA Stelara Label for UC
[3]: Real-World Effectiveness Review (Inflamm Bowel Dis, 2022)
[4]: GEMINI Trial (NEJM, 2013)
[5]: ULTRA Trials (Gastroenterology, 2012)
[6]: OCTAVE Trials (NEJM, 2017)
[7]: UNIFI Long-Term Extension (J Crohns Colitis, 2022)